Chris Degnan - 13 Mar 2023 Form 4 Insider Report for Galera Therapeutics, Inc. (GRTX)

Reporting relationship: Chief Financial Officer
Issuer ticker: GRTX
Reported as of: 13 Mar 2023
Net transaction value: +$19,593
SEC form: 4
Accepted by SEC: 14 Mar 2023, 08:30:09 UTC
Prior SEC filing: 28 Feb 2023
Next SEC filing: 09 Oct 2024
Source filing: View source filing
Reporting owner signature: /s/ Chris Degnan

Key filing fact

Chris Degnan filed Form 4 for Galera Therapeutics, Inc. (GRTX) on 14 Mar 2023.

Key facts

This page summarizes Chris Degnan's Form 4 filing for Galera Therapeutics, Inc. (GRTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 Mar 2023, 08:30.

Change

Previous filing in this sequence was filed on 28 Feb 2023.
Current net transaction value: +$19,593.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GRTX transaction

Common Stock

Purchase

Transaction value: $19,593
Shares: +10,000
Change %
Price: $1.96^*
Shares after: 10,000
Date: 13 Mar 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.95 to $1.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.